International | Germany
Declaration of Compliance

Declaration of Compliance

Declaration of the board of management and the supervisory board of Biotest AG
in relation to the recommendations contained in the German Corporate Governance Code pursuant to § 161 of the German Act on Public Limited Companies.

 

Since the last declaration of compliance dated 5 March 2009, which referred to the German Corporate Governance Code of 6 June 2008, Biotest AG has complied with all of the recommendations of the German Corporate Governance Code in that version with one exception.

  • Biotest AG has not taken up the recommendation in Section 5.3.3 of the German Corporate Governance Code to set up a Supervisory Board nomination committee. Elections to the Supervisory Board are not due for two years. Biotest AG’s Supervisory Board only comprises four shareholder representatives. Biotest AG continues to consider setting up a committee from the small number of shareholder representatives to be unnecessary. The improvement in transparency of the selection procedure at which the recommendation is aimed is also ensured at Biotest AG in full meetings of the Supervisory Board.

The Board of Management and Supervisory Board further declare that all other recommendations of the German Corporate Governance Code in its version from 18 June 2009 are complied with.

Biotest AG has not adopted the recommendation in Section 3.8 of the German Corporate Governance Code:

The D&O policy taken out by the Company for members of the Board of Management does not include a deductible of 10% of the loss up to at least the amount of one and a half times the fixed annual compensation of the Board of Management member. Biotest AG is of the opinion that a deductible of this size has not been necessary in the past with regard to the responsibility and motivation of the members of the Board of Management in performing their duties. Biotest AG intends to add a deductible of this amount to its D&O policy for members of the Board of Management in implementation of Section 93 (2) (3) of the German Stock Corporation Act (AktG) by 30 June 2010.

With reference to the above, Biotest AG has not yet agreed a corresponding deductible for the D&O policy for members of the Supervisory Board.


Dreieich, 09 March 2010


For the Board of Management
For the Supervisory Board

 
Prof. Dr. Gregor Schulz Dr. Michael Ramroth Dr. Thorlef Spickschen
Declaration of Compliance

Declaration of Compliance

Declaration by the Biotest AG Board of Management and Supervisory Board
on the recommendations of the German Corporate Governance Code in accordance with Section 161 of the German Stock Corporation Act (AktG)

 

Since the last declaration of compliance dated 17 March 2011, which referred to the German Corporate Governance Code of 26 May 2010, Biotest AG has complied with all of the recommendations of the German Corporate Governance Code in said version with the following exceptions:

  • Biotest AG has not followed the recommendation in Section 5.3.3 of the German Corporate Governance Code to form a Supervisory Board nomination committee. Biotest AG’s Supervisory Board comprises only four shareholder representatives. The improvement in transparency of the selection procedure at which the recommendation is aimed is also ensured at Biotest AG in full meetings of the Supervisory Board.
  • Biotest AG does not currently follow the recommendation in Section 3.8 (3) of the German Corporate Governance Code to set a deductible in D&O liability insurance coverage for members of the Supervisory Board in the amount prescribed under Section 93, Paragraph 2, Sentence 3 of the German Stock Corpora- tion Act (AktG). Biotest AG has established in its view an appropriate deductible for members of its Super- visory Board. However, this does not meet the deductible amount for Supervisory Board members required by law. In Biotest’s view, an increase in the deductible set would be out of proportion with current remu- neration for Supervisory Board duties.

The Board of Management and Supervisory Board further declare their compliance with all other recom- mendations of the German Corporate Governance Code as amended on 26 May 2010, with the following exceptions:

  • The revisions to the German Corporate Governance Code of 26 May 2010 include new recommendations under Section 5.4.1 of the German Corporate Governance Code, which state that the Supervisory Board is to establish specific targets with regard to its composition, taking into account the international activities of the Company, potential conflicts of interest, an age limit for Supervisory Board members (to be defined) and diversity in light of the Company’s specific situation. These specific targets should include adequate female representation. The Supervisory Board must take these targets into account when making recom- mendations to the selection committees. The targets and the status of their implementation are to be published in the Corporate Governance Report. The Supervisory Board of Biotest AG has already set a specific target with regard to the maximum age of its members. In addition, female members already make up one-third of the Supervisory Board. An internal analysis found that, in the case of Biotest AG, due to past and also future above-average participation by women on the Supervisory Board, no express tar- gets are required. To this extent, an exemption from Section 5.4.1 (2) of the German Corporate Govern- ance Code is declared. Accordingly, corresponding statements in the Corporate Governance Report cannot be made. Therefore, an exemption from Section 5.4.1 (3) of the German Corporate Governance Code is also declared.

Dreieich, Germany, 20 March 2012


For the Board of Management
For the Supervisory Board

 
Prof. Dr. Gregor Schulz Dr. Michael Ramroth Dr. Thorlef Spickschen